Mol Cell Biochem
To answer this GR siRNA study was done, where we find
that DX10 either as alone or in combination with WP is
working through GR. JAK/STAT3 activity is generally
monitored by IL-6 cytokine [26–29]. On the other hand,
some literature suggested that IL-6 production is inhibited
by Dex through its receptor GR [33]. Thus GR may play an
indirect role towards maintaining JAK/STAT3 activity.
Previously Obrador et al., reported that GR-knocking down
References
1
2
. Gottesman MM (2002) Mechanisms of cancer drug resistance.
Annu Rev Med 53:615–627
. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA,
Kinzler KW (2013) Cancer genome landscapes. Science
339:1546–1558
3
4
. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M,
Snyder N, Sarkar S (2014) Drug resistance in cancer: an over-
view. Cancers 6:1769–1792
. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha
C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus
chemotherapy in metastatic triple-negative breast cancer. N Engl
J Med 364:205–214
(
using GR siRNA) causes down-modulation of IL-6 release
in B16-melanoma cells [34]. Therefore it could be expec-
ted that GR siRNA pre-treated cells could show the down-
modulation of IL-6 in DX10?WP treatment. In this regard,
we check the IL-6 status and find out that IL-6 amount
clearly decreased in all DX10 treatment. However, reduc-
tion of IL-6 by Dex treatment (much lesser extent compare
to DX10) doesn’t lead to similar extent of p-STAT3 inhi-
bitory effect (data not shown). The mechanistic study
proves that combination treatment arrests the cell in dif-
ferent phases of the cell cycle followed by induction of
early apoptosis and finally cell death. Since this new
combinational strategy shows its efficacy in vitro, thus to
extrapolate and validate the result we carried out in vivo
study. Where combination treatment inhibits tumor growth
significantly and blocks the STAT3 activation in tumor
lesion, which is fully consistent with our in vitro
observation.
5
. Amadori D, Cecconetto L (2006) Gemcitabine and taxanes in
metastatic breast cancer. Ann Oncol 17:173–176
6. Rocha LC, Sherman CA, Brescia FJ, Brunson CY, Green MR
2001) Irinotecan/gemcitabine combination chemotherapy in
pancreatic cancer. Oncology 15:46–51
(
7
. Akira S (1999) Functional roles of STAT family proteins: lessons
from knockout mice. Stem Cells 17:138–146
8. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA
et al (2001) Constitutive activation of Stat3 by the Src and JAK
tyrosine kinases participates in growth regulation of human breast
carcinoma cells. Oncogene 20:2499–2513
9
. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod
JC, Delobel J et al (1996) STAT-related transcription factors are
constitutively activated in peripheral blood cells from acute leu-
kemia patients. Blood 87:1692–1697
1
1
1
0. Fernandes A, Hamburger AW, Gerwin BI (1999) ErbB-2 kinase
is required for constitutive stat 3 activation in malignant human
lung epithelial cells. Int J Cancer 83:564–570
1. Simonian PL, Grillot DA, Nu n˜ ez G (1997) Bcl-2 and Bcl-XL can
differentially block chemotherapy-induced cell death. Blood
9
0:1208–1216
2. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS (2009)
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo
in breast cancer. Int J Oncol 34:1209–1220
Conclusion
To summarize, in the current study we have developed a
new combination chemotherapeutic using novel DX10 and
WP which showed potent anti-cancer activity through
synergistic inhibition of p-STAT3. Activity of DX10 is GR
mediated and this combination treatment induces early
apoptosis. Findings from melanoma tumor study proved
the synergistic therapeutic benefit where DX10?WP inhi-
bit tumor growth through simultaneous induction of
apoptosis and inhibition of STAT3 activation. Taken
together, the presently reported combination treatment
evokes immense possibilities in development of anti-tumor
therapeutics, particularly against cancer where STAT3
serves as an important oncoprotein.
13. Alas S, Bonavida B (2003) Inhibition of constitutive STAT3
activity sensitizes resistant non-Hodgkin’s lymphoma and mul-
tiple myeloma to chemotherapeutic drug-mediated apoptosis.
Clin Cancer Res 9:316–326
1
4. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH et al
(2003) Glucocorticoid cotreatment induces apoptosis resistance
toward cancer therapy in carcinomas. Cancer Res 63:3112–3120
5. Rutz HP (2002) Effects of corticosteroid use on treatment of solid
tumours. Lancet 360:1969–1970
1
1
6. Rutz HP, Herr I (2004) Interference of glucocorticoids with
apoptosis signaling and host-tumor interactions. Cancer Biol Ther
3
:715–718
1
7. Kriegler AB, Bernardo D, Verschoor SM (1994) Protection of
murine bone marrow by dexamethasone during cytotoxic
chemotherapy. Blood 83:65–71
18. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa
AM et al (2006) Bortezomib plus dexamethasone as induction
treatment prior to autologous stem cell transplantation in patients
with newly diagnosed multiple myeloma: results of an IFM phase
II study. Haematologica 91:1498–1505
Acknowledgements SS and SKM thank Council of Scientific and
Industrial Research (CSIR), Government of India, New Delhi for their
doctoral research fellowships. RB acknowledges financial assistance
from CSIR Network Project Grant [CSC0302, BSC0123], Govt. of
India.
1
9. Sui M, Chen F, Chen Z, Fan W (2006) Glucocorticoids interfere
with therapeutic efficacy of paclitaxel against human breast and
ovarian xenograft tumors. Int J Cancer 119:712–717
2
2
0. Sau S, Banerjee R (2014) Cationic lipid-conjugated dexametha-
sone as a selective antitumor agent. Eur J Med Chem 83:433–447
1. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z et al (2007)
WP1066 disrupts Janus kinase-2 and induces caspase-dependent
Compliance with ethical standards
Conflict of interest The authors declare that there is no conflict of
interest.
123